Editorial: antigenic response to CT‐P13 and infliximab originator in IBD shows similar epitope recognition—evidence from basic science supports safe switching to biosimilars. Authors’ reply

• Published in: Alimentary pharmacology & therapeutics Vol. 48; no. 5; pp. 575 - 576
• Main Authors: Goncalves, J., Magro, F., Danese, S., Lakatos, P. L., Ben‐Horin, S.
• Format: Journal Article
• Language: English
• Published: England Wiley Subscription Services, Inc 01.09.2018
• Subjects: Epitopes; Infliximab; Monoclonal antibodies; Tumor necrosis factor-α

Linked Content This article is linked to Goncalves et al and Pouillon et al papers. To view these articles visit https://doi.org/10.1111/apt.14808 and https://doi.org/10.1111/apt.14847.